For Non-Small Cell Lung Cancer (NSCLC), VAL-083 Demonstrates Effectiveness

Share this content:

the Cancer Therapy Advisor take:

According to new findings presented at the American Association for Cancer Research's (AACR) New Horizons in Cancer Research: Harnessing Breakthroughs - Targeting Cures in Shanghai, China, a new drug compound currently known as VAL-083 was shown to be superior to cisplatin for the treatment of non-small cell lung cancer (NSCLC).

The results demonstrated that VAL-083 is superior to cisplatin in tumors that are either sensitive or resistant to tyrosine kinase inhibitors (TKI), and it was found to have a synergistic effect when combined with cisplatin.

VAL-083 (dianhydrogalactitol) is the first agent in a class of alkylating agents that have a novel cytotoxic mechanism. The drug has demonstrated clinical activity in various types of cancers, including central nervous system tumors, solid tumors, and hematologic cancers. VAL-083 is approved for the treatment of lung cancer and chronic myelogenous leukemia (CML) in China. In the United States, VAL-083 is in a phase 1/2 clinical trial to study its efficacy in the treatment of glioblastoma multiforme.

NSCLC is typically treated with either a TKI, such as gefitinib, or a platinum-containing regimen. Despite improved outcomes seen with the use of TKIs, there are not many options for patients with TKI resistance.

No Silver Bullet for Patient Nonadherence to Oral Anticancer Therapies
VAL-083 was shown to be superior to cisplatin for the treatment of non-small cell lung cancer.

DelMar Pharmaceuticals, Inc., a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR's New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures. The conference takes place October 9th to 12th in Pudong, Shanghai.

"The data presented today showed that VAL-083 is superior to cisplatin in both tumor models that are sensitive and resistant to tyrosine kinase inhibitors and has synergistic effect in combination with cisplatin," said Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals. "This data suggests important clinical and market potential of VAL-083 in non-small cell lung cancer."

READ FULL ARTICLE From News Medical

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs